Dr David Ribeiro, CEO of ProAxsis, will be attending the Anglonordic Life Sciences Conference, taking place in London this week, and will be presenting a company update as part of the Biotech Investment Programme at 2pm on May 31st. This will be the 14th annual meeting of this partnering conference.
Dr Ribeiro said: “This is the first time that we’ll have participated in this event, so I’m very much looking forward to engaging with the attendees from the investor and biotech communities. Our point-of-care test for monitoring active neutrophil elastase in diseases such as COPD and cystic fibrosis is in its final stages of development, so this is an excellent time for us to be meeting prospective partners for this exciting technology.”
Any requests from either pharmaceutical companies or academic researchers for support to measure active proteases or other inflammatory biomarkers can be directed to info@proaxsis.com.
ProAxsis is part of the NetScientific group and is one of the group’s core portfolio companies. The company is also supported by QUBIS, the commercialisation arm of Queens University.
Related News
Following its previous success in the BioMedical Catalyst competition, ProAxsis Limited (www.proaxsis.com) has now gained further support for …
ProAxsis Limited (www.proaxsis.com) is further expanding its ProteaseTag® technology platform, via a project co-funded by the UK’s innovation …
ProAxsis were this week delighted to host His Royal Highness, the Duke of York, at their new laboratory …
